CL2013000492A1 - Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil) fenil]piperazina y sus sales para un tratamiento a largo plazo de una enfermedad del snc que esta asociado con un ligero o con un no aumento de peso - Google Patents
Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil) fenil]piperazina y sus sales para un tratamiento a largo plazo de una enfermedad del snc que esta asociado con un ligero o con un no aumento de pesoInfo
- Publication number
- CL2013000492A1 CL2013000492A1 CL2013000492A CL2013000492A CL2013000492A1 CL 2013000492 A1 CL2013000492 A1 CL 2013000492A1 CL 2013000492 A CL2013000492 A CL 2013000492A CL 2013000492 A CL2013000492 A CL 2013000492A CL 2013000492 A1 CL2013000492 A1 CL 2013000492A1
- Authority
- CL
- Chile
- Prior art keywords
- phenylsulfanyl
- piperazine
- slight
- dimethyl
- phenyl
- Prior art date
Links
- 238000011866 long-term treatment Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title abstract 2
- 230000004584 weight gain Effects 0.000 title abstract 2
- 235000019786 weight gain Nutrition 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201000739 | 2010-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000492A1 true CL2013000492A1 (es) | 2013-06-07 |
Family
ID=44532506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000492A CL2013000492A1 (es) | 2010-08-23 | 2013-02-20 | Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil) fenil]piperazina y sus sales para un tratamiento a largo plazo de una enfermedad del snc que esta asociado con un ligero o con un no aumento de peso |
Country Status (32)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029060B1 (ru) | 2014-01-31 | 2018-02-28 | Эгиш Дьёдьсердьяр Зрт. | Способ получения солей вортиоксетина |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| CN104610195B (zh) * | 2015-01-30 | 2017-06-27 | 上虞京新药业有限公司 | 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途 |
| BR112018003930A2 (pt) | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
| EP0543584B1 (en) * | 1991-11-18 | 1996-05-22 | Lilly Industries Limited | Benzo(b)thiophene-2-carboxamides for the treatment of disorders of the central nervous system |
| US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| US7159383B2 (en) | 2000-10-02 | 2007-01-09 | Rohr, Inc. | Apparatus, method and system for gas turbine engine noise reduction |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| KR101627901B1 (ko) * | 2006-06-16 | 2016-06-13 | 하. 룬트벡 아크티에 셀스카브 | 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진 |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
-
2011
- 2011-08-17 TW TW100129338A patent/TW201212918A/zh unknown
- 2011-08-19 AR ARP110103029A patent/AR082501A1/es not_active Application Discontinuation
- 2011-08-22 LT LTEP11749331.2T patent/LT2608789T/lt unknown
- 2011-08-22 SM SM20170239T patent/SMT201700239T1/it unknown
- 2011-08-22 DK DK11749331.2T patent/DK2608789T4/da active
- 2011-08-22 IL IL224371A patent/IL224371A/en active IP Right Grant
- 2011-08-22 ME MEP-2017-94A patent/ME02674B/me unknown
- 2011-08-22 PL PL11749331.2T patent/PL2608789T5/pl unknown
- 2011-08-22 HU HUE11749331A patent/HUE034155T2/en unknown
- 2011-08-22 CN CN2011800406861A patent/CN103068389A/zh active Pending
- 2011-08-22 SI SI201131177T patent/SI2608789T2/sl unknown
- 2011-08-22 RS RS20170404A patent/RS55851B2/sr unknown
- 2011-08-22 MX MX2013001570A patent/MX349724B/es active IP Right Grant
- 2011-08-22 KR KR1020137004481A patent/KR101816953B1/ko active Active
- 2011-08-22 RU RU2013112890/15A patent/RU2564666C2/ru active
- 2011-08-22 EP EP11749331.2A patent/EP2608789B2/en active Active
- 2011-08-22 AU AU2011295465A patent/AU2011295465B8/en active Active
- 2011-08-22 CA CA2807062A patent/CA2807062C/en active Active
- 2011-08-22 PT PT117493312T patent/PT2608789T/pt unknown
- 2011-08-22 JP JP2013525143A patent/JP5902169B2/ja active Active
- 2011-08-22 SG SG2013007380A patent/SG187649A1/en unknown
- 2011-08-22 ES ES11749331T patent/ES2625142T5/es active Active
- 2011-08-22 BR BR122020025600A patent/BR122020025600A2/pt not_active Application Discontinuation
- 2011-08-22 HR HRP20170608TT patent/HRP20170608T4/hr unknown
- 2011-08-22 BR BR112013002194A patent/BR112013002194A2/pt not_active Application Discontinuation
- 2011-08-22 US US13/812,073 patent/US20130184291A1/en not_active Abandoned
- 2011-08-22 FI FIEP11749331.2T patent/FI2608789T4/fi active
- 2011-08-22 AP AP2013006768A patent/AP3583A/xx active
- 2011-08-22 WO PCT/DK2011/050317 patent/WO2012025123A1/en not_active Ceased
-
2013
- 2013-02-20 CL CL2013000492A patent/CL2013000492A1/es unknown
- 2013-02-21 CO CO13035030A patent/CO6680652A2/es unknown
- 2013-02-22 ZA ZA2013/01385A patent/ZA201301385B/en unknown
-
2017
- 2017-05-10 CY CY20171100501T patent/CY1118886T1/el unknown
-
2018
- 2018-09-07 US US16/124,497 patent/US20190000836A1/en not_active Abandoned
-
2020
- 2020-05-18 US US16/877,108 patent/US20210085674A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/570,998 patent/US20220370439A1/en not_active Abandoned
-
2023
- 2023-10-10 US US18/483,780 patent/US20240293397A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21033236A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| UY34161A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen | |
| MX2021001425A (es) | Compuestos terapeuticos activos y sus usos. | |
| UY35998A (es) | 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA | |
| AR108768A2 (es) | Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CL2013003313A1 (es) | Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8. | |
| CL2014002880A1 (es) | Compuestos derivados de heterociclos nitrogenados o sus sales, inhibidores selectivos de la pde2a; medicamento que los comprende; y su uso para la profilaxis y tratamiento de la esquizofrenia. | |
| CR20110611A (es) | Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil) acetato de 4-(dimetilamino)butilo | |
| UY32535A (es) | Métodos e intermediarios para la preparación de agentes farmacéuticos | |
| CL2012000457A1 (es) | Composicion farmaceutica oral que comprende el compuesto 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]piperazina y sus sales, en donde dicha composicion esta adaptada de manera que dicho compuesto no es liberado en el estomago; y su uso para el tratamiento de trastornos del animo, de ansiedad, de panico, entre otras enfermedades. | |
| EA201500934A1 (ru) | Кардио- и нефропротективная противодиабетическая терапия | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| MX2016012009A (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso. | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| CL2015002309A1 (es) | Proceso de fabricacion de vortioxetina. | |
| CL2016001172A1 (es) | Nuevos inhibidores de dgat2. | |
| DOP2012000058A (es) | Agente terapeutico para trastornos del estado de animo | |
| CO2017005544A2 (es) | Tableta multicapa que contiene fármaco inestable a la luz | |
| CY1118886T1 (el) | Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης | |
| CL2017001467A1 (es) | Compuestos de dihidropirimidin - 2 - ona y sus usos médicos | |
| UY34786A (es) | Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo | |
| MX2017012926A (es) | Inhibidores y sus usos. | |
| UY34931A (es) | ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?. |